Hemophilia A--from basic science to clinical practice.
This article summarizes achievements of basic research and their implementation in clinical treatment of one of the most common inherited bleeding disorders hemophilia A, which is caused by genetic deficiency of coagulation factor VIII (FVIII). We discuss the structure of FVIII, its major interactions in the intrinsic pathway of blood coagulation, and the catabolism of FVIII. We also discuss achievements in the contemporary clinical practice of treatment of hemophilia A. Replacement therapy has substantially improved by development of purification and virus inactivation procedures, allowing preparation of safe and effective therapeutic plasma-derived FVIII concentrates. We give special attention to the principles used in the development of contemporary recombinant FVIII products, which do not inherit a potential risk for viral or prion transmission. Development of FVIII inhibitory antibodies is the major complication of FVIII replacement therapy. We summarize the accumulated knowledge regarding epitopes of FVIII inhibitors and mechanisms by which they inactivate FVIII and discuss approaches to overcome the effects of inhibitors and to prevent their formation by induction of immunotolerance. We also analyze the main concepts and scientific priorities in the gene-therapeutic approach for treatment of hemophilia A.
Klinge
Jens
J
Hospital for Children and Adolescents, University of Erlangen, Erlangen, Germany. Jens.Klinge@kinder.imed.uni-erlangen.de
Ananyeva
Natalya M
NM
Hauser
Charlotte A E
CA
Saenko
Evgueni L
EL
D000818:Animals; D001777:Blood Coagulation; D005169:Factor VIII / Q000235:genetics / Q000502:physiology / Q000627:therapeutic use; D015316:Genetic Therapy; D006467:Hemophilia A / Q000235:genetics / Q000276:immunology / Q000628:therapy; D006801:Humans; D007518:Isoantibodies / Q000097:blood / Q000276:immunology; D013329:Structure-Activity Relationship
D007518:Isoantibodies; D005169:Factor VIII